Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.
You may also be interested in...
New Labeling Limits Patient Population Of Bayer’s Trasylol
Changes are the result of September advisory committee meeting, concerns over renal dysfunction.
New Labeling Limits Patient Population Of Bayer’s Trasylol
Changes are the result of September advisory committee meeting, concerns over renal dysfunction.
Trasylol Clinical Benefit To Be Reviewed By FDA Advisory Committee
Cardiovascular & Renal Drugs Advisory Committee will also consider reports of hypersensitivity and renal and cardiovascular risk linked to Bayer’s aprotinin injection at its Sept. 21 meeting.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: